{"id":"NCT01027884","sponsor":"Santhera Pharmaceuticals","briefTitle":"Phase III Study of Idebenone in Duchenne Muscular Dystrophy (DMD)","officialTitle":"A Phase III Double-Blind, Randomised, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of Idebenone in 10-18 Year Old Patients With Duchenne Muscular Dystrophy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-07","primaryCompletion":"2014-01","completion":"2014-04","firstPosted":"2009-12-09","resultsPosted":"2015-10-19","lastUpdate":"2015-10-19"},"enrollment":65,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Muscular Dystrophy, Duchenne","Ambulatory Care"],"interventions":[{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Idebenone","otherNames":["CATENA®","RAXONE®"]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Idebenone","type":"EXPERIMENTAL"}],"summary":"The aim of this Phase III study was to assess the efficacy of idebenone on pulmonary function, motor function, muscle strength and quality of life in patients with DMD. Furthermore, the safety and tolerability of idebenone was assessed.","primaryOutcome":{"measure":"Change From Baseline in Percent Predicted Peak Expiratory Flow (PEF) at Week 52","timeFrame":"Baseline and Week 52","effectByArm":[{"arm":"Placebo","deltaMin":-8.84,"sd":null},{"arm":"Idebenone","deltaMin":-2.57,"sd":null}],"pValues":[]},"eligibility":{"minAge":"10 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":23,"countries":["United States","Austria","Belgium","France","Germany","Italy","Netherlands","Spain","Sweden","Switzerland"]},"refs":{"pmids":["25907158","28189481"],"seeAlso":["http://www.santhera.com"]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":34},"commonTop":["Nasopharyngitis","Headache","Diarrhoea","Bronchitis","Constipation"]}}